Description_x000D_ Application_x000D_ IRAK-1/4 inhibitor I has been used in various studies to inhibit IRAK1 in hepatoma cell lines and head and neck squamous cell carcinoma (HNSCC) cell lines._x000D_ Packaging_x000D_ 5, 25 mg in glass bottle_x000D_ Biochem/physiol Actions_x000D_ IRAK-1/4 Inhibitor I is a novel benzimidazole that is a potent inhibitor of interleukin-1 receptor-associated kinases 1/4 (IRAK 1/4). IC50 values were 300 nM and 200 nM for IRAK-1 and -4, respectively, and >10,000 nM for a panel of 27 other kinases tested._x000D_ IRAK1 overexpression leads to the development of head and neck squamous cell carcinoma (HNSCC). Therefore, IRAK-1/4 inhibitor I might be a potential therapeutic for HNSCC tumors. Various experimental studies states that IRAK-1/4 inhibitor might have a potential to exhibit inhibitory effects on the nuclear factor (NF)-κB signaling pathway._x000D_ Features and Benefits_x000D_ This compound is also offered as part of Sigma′s Library of Pharmacologically Active Compounds (LOPAC®1280), a biologically annotated collection of high-quality, ready-to-screen compounds. Click here to learn more._x000D_ Legal Information_x000D_ LOPAC is a registered trademark of Sigma-Aldrich Co. LLC